Effect of home-based telemonitoring using mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation: randomized controlled trial.
BACKGROUND
Telemonitoring of patients with chronic heart failure (CHF) is an emerging concept to detect early warning signs of impending acute decompensation in order to prevent hospitalization.


OBJECTIVE
The goal of the MOBIle TELemonitoring in Heart Failure Patients Study (MOBITEL) was to evaluate the impact of home-based telemonitoring using Internet and mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation.


METHODS
Patients were randomly allocated to pharmacological treatment (control group) or to pharmacological treatment with telemedical surveillance for 6 months (tele group). Patients randomized into the tele group were equipped with mobile phone-based patient terminals for data acquisition and data transmission to the monitoring center. Study physicians had continuous access to the data via a secure Web portal. If transmitted values went outside individually adjustable borders, study physicians were sent an email alert. Primary endpoint was hospitalization for worsening CHF or death from cardiovascular cause.


RESULTS
The study was stopped after randomization of 120 patients (85 male, 35 female); median age was 66 years (IQR 62-72). The control group comprised 54 patients (39 male, 15 female) with a median age of 67 years (IQR 61-72), and the tele group included 54 patients (40 male, 14 female) with a median age of 65 years (IQR 62-72). There was no significant difference between groups with regard to baseline characteristics. Twelve tele group patients were unable to begin data transmission due to the inability of these patients to properly operate the mobile phone ("never beginners"). Four patients did not finish the study due to personal reasons. Intention-to-treat analysis at study end indicated that 18 control group patients (33%) reached the primary endpoint (1 death, 17 hospitalizations), compared with 11 tele group patients (17%, 0 deaths, 11 hospitalizations; relative risk reduction 50%, 95% CI 3-74%, P = .06). Per-protocol analysis revealed that 15% of tele group patients (0 deaths, 8 hospitalizations) reached the primary endpoint (relative risk reduction 54%, 95% CI 7-79%, P= .04). NYHA class improved by one class in tele group patients only (P< .001). Tele group patients who were hospitalized for worsening heart failure during the study had a significantly shorter length of stay (median 6.5 days, IQR 5.5-8.3) compared with control group patients (median 10.0 days, IQR 7.0-13.0; P= .04). The event rate of never beginners was not higher than the event rate of control group patients.


CONCLUSIONS
Telemonitoring using mobile phones as patient terminals has the potential to reduce frequency and duration of heart failure hospitalizations. Providing elderly patients with an adequate user interface for daily data acquisition remains a challenging component of such a concept.
Scherr
Daniel
D
Department of Cardiology, Medical University Graz, Graz, Austria. friedrich.fruhwald@medunigraz.at
Kastner
Peter
P
Kollmann
Alexander
A
Hallas
Andreas
A
Auer
Johann
J
Krappinger
Heinz
H
Schuchlenz
Herwig
H
Stark
Gerhard
G
Grander
Wilhelm
W
Jakl
Gabriele
G
Schreier
Guenter
G
Fruhwald
Friedrich M
FM
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure; D001835:Body Weight; D040421:Cell Phone; D034742:Electronic Mail; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy / Q000534:rehabilitation / Q000628:therapy*; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D018579:Patient Selection; D010820:Physicians; D011369:Professional-Patient Relations; D017216:Telemedicine / Q000379:methods*; D013686:Telemetry / Q000379:methods*
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors
J Am Coll Cardiol. 1999 Mar;33(3):734-42
10080475
J Telemed Telecare. 2004;10(2):113-7
15068649
Cardiology. 2008;111(2):134-9
18376125
Am Heart J. 2003 Oct;146(4):705-12
14564327
Stud Health Technol Inform. 2007;129(Pt 1):112-6
17911689
J Telemed Telecare. 2006;12(5):255-61
16848939
J Med Internet Res. 2005 Mar 26;7(1):e8
15829480
BMJ. 2007 May 5;334(7600):942
17426062
Circulation. 2007 Oct 2;116(14):1549-54
17846286
Circulation. 2007 Sep 25;116(13):1482-7
17724259
Arch Intern Med. 2008 Feb 11;168(3):316-24
18268174
Eur J Heart Fail. 2009 Mar;11(3):312-8
19228800
Eur J Heart Fail. 2007 Nov;9(11):1104-11
17942364
Eur J Heart Fail. 2001 Dec;3(6):723-30
11738225
Int J Cardiol. 2007 Sep 3;120(3):371-9
17189654
BMJ. 2005 Aug 20;331(7514):425
16061499
Am J Cardiol. 1999 Oct 1;84(7):860-2, A8
10513789
Int J Cardiol. 2009 Jan 9;131(2):192-9
18222552
J Am Coll Cardiol. 2005 May 17;45(10):1654-64
15893183
J Med Internet Res. 2004 May 14;6(2):e12
15249261
Eur Heart J. 2005 Jun;26(11):1115-40
15901669
J Am Coll Cardiol. 2005 Sep 20;46(6):1144-78
16168305
Eur J Heart Fail. 2009 Mar;11(3):319-25
19174529
Circulation. 2006 Dec 5;114(23):2466-73
17116767